IVVD vs ADMA vs ALNY vs ARCT vs REGN vs KO

For growth investors, Invivyd, Inc.

(IVVD) is the stronger pick with 110. 5% revenue growth year-over-year, versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). ADMA Biologics, Inc. (ADMA) offers the better valuation at 13. 7x trailing P/E (9. 9x forward), making it the more compelling value choice. Analysts rate Invivyd, Inc. (IVVD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ADMA Biologics, Inc.

(ADMA) is the cheapest at 13. 7x versus Alnylam Pharmaceuticals, Inc. at 121. 4x. On forward P/E, ADMA Biologics, Inc. is actually cheaper at 9. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 08x versus The Coca-Cola Company's 2. 26x.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +346. 2%, compared to -96. 3% for Invivyd, Inc. (IVVD). Over 10 years, the gap is even starker: ALNY returned +366. 4% versus IVVD's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Arcturus Therapeutics Holdings Inc. 's 2. 46β — meaning ARCT is approximately -1331% more volatile than KO relative to the S&P 500. On balance sheet safety, Invivyd, Inc. (IVVD) carries a lower debt/equity ratio of 1% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Invivyd, Inc.

(IVVD) is pulling ahead at 110. 5% versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -98. 2% for Invivyd, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -111. 5% for ARCT. At the gross margin level — before operating expenses — ARCT leads at 95. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 08x versus The Coca-Cola Company's 2. 26x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, ADMA Biologics, Inc. (ADMA) trades at 9. 9x forward P/E versus 37. 7x for Alnylam Pharmaceuticals, Inc. — 27. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IVVD: 1133. 8% to $9. 50.

In this comparison, KO (2.

5% yield), REGN (0. 6% yield) pay a dividend. IVVD, ADMA, ALNY, ARCT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Invivyd, Inc. (IVVD) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, IVVD: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IVVD (Healthcare) and ADMA (Healthcare) and ALNY (Healthcare) and ARCT (Healthcare) and REGN (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IVVD is a small-cap high-growth stock; ADMA is a small-cap high-growth stock; ALNY is a mid-cap high-growth stock; ARCT is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; KO is a large-cap quality compounder stock. REGN, KO pay a dividend while IVVD, ADMA, ALNY, ARCT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.